Skip to content
Clinical Trials – home

Klinikum Nuernberg

Verified siteinfo

Germany Prof.-Ernst-Nathan-Strasse 1, St. Johannis, 90419 Nürnberg, Germany

  • 50 trials recruiting
  • Plasma cell myeloma · Non-small cell lung cancer · Acute myeloid leukaemia
  • Adults and children

About Specializations

Klinikum Nuernberg in Nürnberg, Germany specialises in clinical trials of conditions such as Plasma cell myeloma, Non-small cell lung cancer, Acute myeloid leukaemia, Oesophageal adenocarcinoma, and other specialisations. This site conducts important research.

Main research areas of the site

Hematologic Malignancies

The medical center is at the forefront of research in hematologic malignancies, focusing on innovative therapies for conditions such as acute myeloid leukemia and mantle cell lymphoma. The center's work in this area aims to improve treatment outcomes through advanced therapeutic regimens and stem cell transplantation techniques.

  • Acute Myeloid Leukemia (AML)
  • Mantle Cell Lymphoma
  • Multiple Myeloma

By integrating cutting-edge research with clinical practice, the center is enhancing the efficacy of existing treatments and exploring new therapeutic avenues.

Oncology

Specializing in oncology, the center conducts pivotal studies on various cancers, including non-small cell lung cancer and gastrointestinal tumors. The research focuses on novel drug combinations and personalized medicine approaches to improve patient survival and quality of life.

  • Non-Small Cell Lung Cancer (NSCLC)
  • Gastrointestinal Tumors
  • Melanoma

The center's commitment to oncology research is evident in its efforts to develop targeted therapies and immunotherapies that address the unique genetic and molecular profiles of tumors.

Cardiology

In the field of cardiology, the center is pioneering research on acute coronary syndromes and atrial fibrillation. The focus is on optimizing antiplatelet and anticoagulation therapies to reduce cardiovascular events while minimizing bleeding risks.

  • Acute Coronary Syndromes
  • Atrial Fibrillation

Through its research, the center is advancing the understanding of cardiovascular diseases and improving therapeutic strategies for better patient outcomes.

Respiratory Diseases

The center is a leader in research on respiratory diseases, particularly focusing on chronic obstructive pulmonary disease and chronic lung disease in premature infants. The research aims to develop new treatments that reduce disease burden and improve respiratory function.

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Chronic Lung Disease in Premature Infants

By exploring innovative therapeutic approaches, the center is contributing to the advancement of respiratory care and enhancing the quality of life for patients with chronic respiratory conditions.

Autoimmune and Inflammatory Diseases

Research at the center includes a strong focus on autoimmune and inflammatory diseases, such as psoriatic arthritis and systemic sclerosis. The center is investigating the potential of immunosuppressive therapies and biologics to manage disease activity and improve patient outcomes.

  • Psoriatic Arthritis
  • Systemic Sclerosis

Through its research, the center is enhancing the understanding of these complex diseases and developing strategies to improve patient care and quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Prof.-Ernst-Nathan-Strasse 1, St. Johannis90419 NürnbergGermany
Recruiting now
50 trials
Conditions studied
89
Partner status
Verified site

More sites in NürnbergGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

107 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Breast cancer

Recruiting

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Arsenic Trioxide

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.